This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Beyond the Abstracts
Urologic Oncology
Prostate Cancer
Beyond the Abstracts
Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective? "Beyond the Abstract," by Ben Vanneste, MD
June 23, 2015
Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies, "Beyond the Abstract," by Osamu Ukimura, MD, PhD
June 22, 2015
The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer, "Beyond the Abstract," by Robert W. Veltri, PhD
June 17, 2015
Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease, "Beyond the Abstract," by Florence K. Keane, MD and Anthony V. D’Amico, MD, PhD
June 10, 2015
MRI-targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men, "Beyond the Abstract," by Fouad Aoun, MD, MSc
June 8, 2015
Surgical treatment of high-risk prostate cancer, "Beyond the Abstract," by R. Soares and C. G. Eden
June 5, 2015
Parameters of two-dimensional perineal ultrasonography for evaluation of urinary incontinence after radical prostatectomy, "Beyond the Abstract," by Danilo Souza Lima da Costa Cruz, MD
June 4, 2015
Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells, "Beyond the Abstract," by Adam Hirst
June 3, 2015
Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy, "Beyond the Abstract," by Kelvin Alexander Moses, MD, PhD
June 3, 2015
Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer, "Beyond the Abstract," by Jeremy Y.C. Teoh and Anthony C.F. Ng
June 1, 2015
Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level, "Beyond the Abstract," by Jeremy Y.C. Teoh and Ming-Kwong Yiu
May 29, 2015
A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy, "Beyond the Abstract," by Shane Mesko, BS and Mitchell Kamrava, MD
May 29, 2015
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone, "Beyond the Abstract," by Ugo De Giorgi
May 28, 2015
Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy, "Beyond the Abstract," by Anthony S. Bates and Tim R. Terry
May 28, 2015
Differential requirement for Src-family tyrosine kinases in the initiation, progression and metastasis of prostate cancer, "Beyond the Abstract," by Irwin H. Gelman, PhD
May 27, 2015
A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer, "Beyond the Abstract," by Richard Wilder, MD, MS, MBA
May 27, 2015
Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer, "Beyond the Abstract," by Jeremy Jones, PhD
May 26, 2015
A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer, "Beyond the Abstract," by Fouad Aoun, MD, MSc
May 26, 2015
A validation study of the cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer in a Turkish patient population in different age categories, "Beyond the Abstract," by Bulent Erol, MD
May 14, 2015
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance), "Beyond the Abstract," by Jai N. Patel, PharmD
May 12, 2015
Page 32 of 56
Start
Prev
27
28
29
30
31
32
33
34
35
36
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free